Fredrik Dahl

Pixelgen Technologies AB is a company that was founded in 2020 by a team of experienced innovators and entrepreneurs. The company is based in Solna, Sweden. Pixelgen has developed a DNA-based visualization technology called molecular pixelation, which analyzes cell surface proteins to gain insights into cellular activity. The Swedish company aims to deepen the understanding of biology for a healthier world with their technology. Pixelgen's products are covered by one or more claims of patents or pending patent applications. The company was founded by Johan Erik Simon Fredriksson, Alvaro Martinez Barrio, Filip Karlsson, and Fredrik Dahl, with Johan Erik Simon Fredriksson serving as the CEO since 2020.

Vanadis Diagnostics AB develops a novel solution for non-invasive prenatal testing based on digital analysis of cell-free DNA. The company was founded by Olle Ericsson and Fredrik Dahl in 2013 and is headquartered in Sollentuna, Sweden.

Halo Genomics AB operates as a genomics company. It offers sample preparation solutions to provide scientists with enabling tools to analyze the genetic foundation of disease. The firm provides reagent kits and a service for the multiplex amplification of exons for targeted re-sequencing that includes selector probe library design and synthesis, target regions amplification, and quality control of the enrichment. The company was founded by Olle Ericsson in 2008 and is headquartered in Uppsala, Sweden.

Moligo Technologies AB is a Swedish company located in Solna that engages in producing ultrapure DNA. The firm was founded in 2019 by Björn Högberg, Cosimo Ducani and Simone Codeluppi. Cosimo Ducani has been the CEO since the company founding. The company says this about itself: Moligo Technologies produces long, ultra-pure, complex DNA at industrial scale using a proprietary enzymatic synthesis process to overcome the challenges of chemical methods. The company's innovative PCR-free "injection-molding" platform can be scaled to produce kilograms of DNA, enough material to enable any cell- or gene-based therapy to go from the lab through clinical trials. With a specialty in complex, ultrapure single-stranded DNA 100 percent sequence verified and more than 10,000 bases long - and at scalable volume - Moligo helps companies take safer, more effective gene-based therapeutics, vaccines, and diagnostics over the finish line and to the patient. Moligo was founded in 2019 and is privately held.